September 10, 2014 – Sub-Saharan Africa is facing a healthcare tipping point. Policy and resources are mainly dedicated to fighting infectious diseases today. HIV, malaria and tuberculosis are the big targets. But over the next 15 years chronic disease…
Basel, September 2, 2014 – Janko Ignjatovic of Serbia has been selected as one of three individual winners of the Novartis International BioCamp held in Basel last week. Mr. Ignjatovic, who studies pharmacy at the University of Belgrade, came to the ev…
August 29, 2014 – Novartis has a strong history of CR activities, and transparent reporting is a central part of our commitment to corporate responsibility. We have publicly reported on our performance in this area since 2000 through our Annual Report …
August 29, 2014 – Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedica…
First generic version of oncology medicine bortezomibe in BrazilNew therapeutic option for patients suffering from multiple myelomaSão Paulo, August 26, 2014 – Sandoz, the generic pharmaceutical division of Novartis, today announces the market introduc…
August 21, 2014 – Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedica…
Mexico’s Health Authority (COFEPRIS) grants marketing authorization for Airflusal® Forspiro®Approval for 50-100mg, 50-250mg and 50-500mg dosage formsProduct to be branded IrFlosolTM Forspiro® in MexicoAirflusal® Forspiro® already launched in four Europ…
Sandoz Germany launches Vitaros®, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerabilityLaunch…
Sandoz Sweden launches Vitaros®, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerabilityLaunch …
Sandoz is the first company to announce it has filed for approval of a biologic under the biosimilars pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA)FDA’s acceptance of Sandoz’s filing is an important first step in…